Latest IMS Health's World Review now available

25 March 2001

IMS Health's latest annual World Review is now available and, accordingto the company, offers greater coverage than previously, giving insight into pharmaceutical companies, products and countries. This is supplied in CD-Rom format or via the Internet or Intranet, at a price of $14,600 per (first) copy.

"For a deeper level of insight and scope," says IMS, also available is World Review Analyst, which offers 11 new tables covering drug sales by region, leading international products of the top companies worldwide and sales of New Chemical Entities. In addition, cut-offs have been increased to give a much broader view of the market. This is also available in CD-Rom format, and costs $22,900 per (first) copy.

For further information and orders, fax World Review at: +44 (0)20 7393 5999, or visit the IMS Health web site at: www.imshealth.com/global.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight